DE69231935T2 - Konjugat enthaltend ein geradkettiges organisches polymer mit gebundenen sulfatierten glukosaminoglukanen wie zum beispiel heparin, seine herstellung, verwendung und ein entsprechendes substrat - Google Patents

Konjugat enthaltend ein geradkettiges organisches polymer mit gebundenen sulfatierten glukosaminoglukanen wie zum beispiel heparin, seine herstellung, verwendung und ein entsprechendes substrat

Info

Publication number
DE69231935T2
DE69231935T2 DE69231935T DE69231935T DE69231935T2 DE 69231935 T2 DE69231935 T2 DE 69231935T2 DE 69231935 T DE69231935 T DE 69231935T DE 69231935 T DE69231935 T DE 69231935T DE 69231935 T2 DE69231935 T2 DE 69231935T2
Authority
DE
Germany
Prior art keywords
glucosaminoglucans
heparine
sulfated
bonded
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231935T
Other languages
English (en)
Other versions
DE69231935D1 (de
Inventor
Rolf Larsson
David Westberg
Birgitta Formgren
Anders Uhlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CORLINE SYSTEMS UPPSALA AB
Original Assignee
CORLINE SYSTEMS UPPSALA AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CORLINE SYSTEMS UPPSALA AB filed Critical CORLINE SYSTEMS UPPSALA AB
Publication of DE69231935D1 publication Critical patent/DE69231935D1/de
Application granted granted Critical
Publication of DE69231935T2 publication Critical patent/DE69231935T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69231935T 1991-09-26 1992-09-25 Konjugat enthaltend ein geradkettiges organisches polymer mit gebundenen sulfatierten glukosaminoglukanen wie zum beispiel heparin, seine herstellung, verwendung und ein entsprechendes substrat Expired - Lifetime DE69231935T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9102798A SE470006B (sv) 1991-09-26 1991-09-26 Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
PCT/SE1992/000672 WO1993005793A1 (en) 1991-09-26 1992-09-25 A novel conjugate, its preparation and use and a substrate prepared with the conjugate

Publications (2)

Publication Number Publication Date
DE69231935D1 DE69231935D1 (de) 2001-08-16
DE69231935T2 true DE69231935T2 (de) 2002-04-04

Family

ID=20383839

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231935T Expired - Lifetime DE69231935T2 (de) 1991-09-26 1992-09-25 Konjugat enthaltend ein geradkettiges organisches polymer mit gebundenen sulfatierten glukosaminoglukanen wie zum beispiel heparin, seine herstellung, verwendung und ein entsprechendes substrat

Country Status (7)

Country Link
US (1) US5529986A (de)
EP (1) EP0658112B1 (de)
JP (1) JP3398150B2 (de)
AU (1) AU2664692A (de)
DE (1) DE69231935T2 (de)
SE (1) SE470006B (de)
WO (1) WO1993005793A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US6486140B2 (en) 1994-07-19 2002-11-26 Medicarb Ab Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site
US5532311A (en) * 1995-02-01 1996-07-02 Minnesota Mining And Manufacturing Company Process for modifying surfaces
US5583213A (en) * 1995-05-12 1996-12-10 Minnesota Mining And Manufacturing Company Process to activate sulfated polysaccharides
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
GB9608882D0 (en) 1996-04-30 1996-07-03 Luthra Ajay K Non-thrombogenic and anti-thrombogenic polymers
US6011082A (en) * 1997-06-02 2000-01-04 Pharmacia & Upjohn Ab Process for the modification of elastomers with surface interpreting polymer networks and elastomers formed therefrom
US6943204B2 (en) * 1997-06-02 2005-09-13 Advanced Medical Optics Uppsala Ab Process for the modification of elastomers with surface interpenetrating polymer networks and elastomers formed therefrom
US5945457A (en) * 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
US5972903A (en) * 1997-10-07 1999-10-26 Regents Of The University Of California Corporation Method for promoting angiogenesis using heparin and adenosine
EP1021195A1 (de) * 1997-10-07 2000-07-26 The Regents Of The University Of California Behandlung okklusiver peripheral-gefässkrankheiten und koronarkrankheiten mit kombinationen aus heparin und adenosin-a2-agonisten, oder mit adenosin
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
JP3936058B2 (ja) * 1998-03-12 2007-06-27 株式会社メニコン コンタクトレンズ用液剤
US6894022B1 (en) * 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
JP4606586B2 (ja) * 1998-11-10 2011-01-05 株式会社ネーテック 機能性キトサン誘導体
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
EP1172386B1 (de) * 1999-04-02 2004-12-08 Netech Inc. Funktionalisiertes polymer von glykosaminoglycan, arzneimittel und medizinische instrumente zu seiner herstellung
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
SE515295C2 (sv) * 1999-11-23 2001-07-09 Medicarb Ab Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat
WO2002081619A1 (fr) * 2001-04-02 2002-10-17 Netech Inc. Complexes de glycosaminoglycane/collagene et utilisation
SE523216C2 (sv) * 2001-07-27 2004-04-06 Zoucas Kirurgkonsult Ab Heparinstent
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
US20030161938A1 (en) * 2002-02-22 2003-08-28 Bo Johnson Composition and method for coating medical devices
US7438925B2 (en) * 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
JP4759736B2 (ja) * 2003-12-26 2011-08-31 国立大学法人お茶の水女子大学 シュードプロテオグリカンおよびその用途
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
AU2005318097A1 (en) * 2004-12-22 2006-06-29 Kuros Biosurgery Ag Michael-type addition reaction functionalised peg hydrogels with factor XIIIA incorporated biofactors
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
CA2592973A1 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
EP1898937B1 (de) 2005-07-01 2012-11-28 Corline Systems AB Heparinbeschichtung von biologischem gewebe
IL305084A (en) 2005-08-24 2023-10-01 Immunogen Inc A process for preparing purified drug compounds
CA2620406A1 (en) 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP1924246B1 (de) 2005-09-15 2015-10-21 Genzyme Corporation Beutelformulierung für aminpolymere
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US8986713B2 (en) 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
SE530716C2 (sv) 2006-10-06 2008-08-19 Corline Systems Ab Molekylärt aggregat på ett substrat
ATE543520T1 (de) 2007-04-13 2012-02-15 Kuros Biosurgery Ag Polymergewebeversiegelung
CA2710798A1 (en) * 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
LT2437790T (lt) 2009-06-03 2019-06-10 Immunogen, Inc. Konjugavimo būdai
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
US20130052155A1 (en) * 2009-11-09 2013-02-28 Drexel University Compositions and Methods for Treating a Disorder or Defect in Soft Tissue
BR112013023241B1 (pt) 2011-03-11 2019-07-02 W. L. Gore & Associates, Inc. Molécula de polímero catiônico hiper ramificado e dispositivo
EP2686027B1 (de) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmazeutische formulierung zur verwendung für die wirbelsäulenfusion
KR20220009505A (ko) * 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
EP3821897B1 (de) 2011-12-22 2022-07-06 Corline Biomedical AB Mittel und verfahren zur behandlung von blutgefässen
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US20140272232A1 (en) * 2013-03-15 2014-09-18 Bard Access Systems, Inc. Antithrombic coatings and uses thereof
US20140364368A1 (en) * 2013-06-06 2014-12-11 Massachusetts Institute Of Technology Stimulus responsive nanocomplexes and methods of use thereof
JP6435863B2 (ja) * 2013-11-28 2018-12-12 東レ株式会社 抗血栓性材料
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
EP3095509A1 (de) * 2015-05-18 2016-11-23 Defymed Funktionalisierte membrane für biokünstliche organe
EP3318294A1 (de) 2016-11-08 2018-05-09 Defymed Kit zur in situ-ausgabe einer verbindung von interesse
EP3892259A1 (de) 2020-04-09 2021-10-13 Defymed Membranen für medizinische vorrichtungen
CA3179703A1 (en) 2020-04-09 2021-10-14 Defymed Membranes for medical devices

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2148011C3 (de) * 1970-10-05 1978-11-09 Aminkemi Ab Verfahren zum Herstellen nichtthrombogener Kunststoffoberflächen
SE400173B (sv) * 1975-03-20 1978-03-20 Aminkemi Ab Forfarande vid stabilisering av en hepariniserad yta innehallande vid blodkontakt utlosbart heparin
US4239664A (en) * 1978-10-31 1980-12-16 Research Corporation Anti-thrombogenic PVP-heparin polymer
US4415490A (en) * 1979-07-24 1983-11-15 Nippon Zeon Co., Ltd. Non-thrombogenic material
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
CH665954A5 (fr) * 1985-07-08 1988-06-30 Battelle Memorial Institute Substrat dont la surface presente une activite antithrombogenique.
JPS6238172A (ja) * 1985-08-12 1987-02-19 株式会社　高研 抗血栓性医用材料の製造方法
NL8701337A (nl) * 1987-06-09 1989-01-02 Sentron V O F Substraat voorzien van een bloedcompatibel oppervlak, verkregen door koppeling aan het oppervlak van een fysiologisch aktieve stof met remmende invloed op de vorming van bloedstolsels en/of in staat om gevormde bloedstolsels af te breken, alsmede werkwijze ter vervaardiging van het substraat.
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
FR2631970B1 (fr) * 1988-05-24 1993-12-24 Sanofi N-polyosyl-polypeptides
DE68920925T2 (de) * 1988-07-11 1995-06-22 Terumo Corp Medizinisches Material und Gerät.

Also Published As

Publication number Publication date
WO1993005793A1 (en) 1993-04-01
US5529986A (en) 1996-06-25
EP0658112A1 (de) 1995-06-21
DE69231935D1 (de) 2001-08-16
SE9102798D0 (sv) 1991-09-26
JPH06510783A (ja) 1994-12-01
JP3398150B2 (ja) 2003-04-21
EP0658112B1 (de) 2001-07-11
SE9102798L (sv) 1993-03-27
AU2664692A (en) 1993-04-27
SE470006B (sv) 1993-10-25

Similar Documents

Publication Publication Date Title
DE69231935T2 (de) Konjugat enthaltend ein geradkettiges organisches polymer mit gebundenen sulfatierten glukosaminoglukanen wie zum beispiel heparin, seine herstellung, verwendung und ein entsprechendes substrat
DE69218039D1 (de) Polymerartikel, wie zum Beispiel ein medizinischer Katheter und Herstellungsverfahren
NO890848L (no) Roer omfattende sammensatte lag med forskjellig elastisitetsmodul.
DE69729158D1 (de) Auf einem Substrat hergestellte Quantendrähte und deren Herstellungsverfahren, sowie ein Bauteil mit Quantendrähten auf einem Substrat
DE59103973D1 (de) Tragevorrichtung mit Gewichtsausgleich für ein Operationsmikroskop.
DE68928643T2 (de) Mit einer lichtdurchlässigen Phasenaustausch-Tinte bedrucktes Substrat und Verfahren zu seiner Herstellung
DE69415275D1 (de) Gewobene, rohrförmige prothese mit hoher festigkeit
DE68920676T2 (de) Organisches Polymer, leitfähiges organisches Polymer, Produktionsmethoden und Verwendung derselben.
DE3867471D1 (de) Variabel vernetzter polymertraeger.
DE69020509T2 (de) Mit selbstklebender Polysiloxankautschukzusammensetzung beschichtete Gewebe.
DE68913806D1 (de) Elektronische Packungsanordnung mit biegsamem Träger und Verfahren zu ihrer Herstellung.
DE59205177D1 (de) Beschichtetes transparentes Substrat, Verwendung hiervon, Verfahren und Anlage zur Herstellung der Schichten, und Hafnium-Oxinitrid (HfOxNy) mit 1,5 x/y 3 und 2,6 n 2,8
DE3770958D1 (de) Substrat mit schleifkoerner tragender haftschicht, seine herstellung und schleifmaterial.
DE68915440T2 (de) Anordnung für ein durchsichtiges bedeckungselement mit einer elektrochromatischen schicht.
DE68902608D1 (de) Pulverfoermiges material, das einen platinhydrosilylierungskatalysator und ein polysilan enthaelt.
DE69107171T2 (de) Trocknungsverfahren und -vorrichtung für ein beschichtetes Substrat.
DE69107170D1 (de) Trocknungsverfahren und -vorrichtungen für ein beschichtetes Substrat.
DE69203067D1 (de) Mehrschichtiges Verbandmaterial mit einem Silikonpolymer als Substrat.
DE3881040T2 (de) Spinndüse mit sieben Löchern.
DE69020778D1 (de) Geformter Gegenstand, angepasst um an ein Substrat befestigt zu werden und Verfahren zu seiner Herstellung.
DE68912315D1 (de) Testverfahren für chlamydia unter verwendung einer basisbehandlung.
DE58902285D1 (de) Elastische verbindungsvorrichtung, insbesondere mit integrierter kraftmesseinrichtung und ein verfahren zu deren herstellung.
DE3879236T2 (de) Organopolysiloxane mit silethylenbindungen.
DE58906267D1 (de) Pfropfcopolymerisate, ein Verfahren zu deren Herstellung und deren Verwendung.
DE3863126D1 (de) Vinylcopolymerisate mit aufgepfropften polycarbonatketten, ihre herstellung und verwendung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 658112

Country of ref document: EP